Welcome to Light Sciences Oncology

Light Sciences Oncology (LSO) is developing Talaporfin Sodium for the treatment of benign prostatic hyperplasia (BPH) and various solid tumors. Talaporfin Sodium is a water-soluble drug targeted by a small, single-use, disposable drug activator included with the drug. Talaporfin Sodium is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment of patients in a Phase 3 trial of Talaporfin Soduim in hepatocellular carcinoma (HCC), a Phase 3 trial for metastatic colorectal cancer (MCRC) and Phase 2 clinical trials in benign prostatic hyperplasia (BPH).  The company has positioned its technology to benefit an increasing number of patients with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally capable and efficient team. Talaporfin Sodium has been identified during development as Litx™.